MK-8776 (SCH 900776)

For research use only.

Catalog No.S2735

36 publications

MK-8776 (SCH 900776) Chemical Structure

CAS No. 891494-63-6

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 1921.21 In stock
RMB 1733.35 In stock
RMB 3015.42 In stock
RMB 7966.05 In stock
RMB 20229.30 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MK-8776 (SCH 900776) has been cited by 36 publications

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
Targets
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
In vitro

SCH 900776 is a less potent inhibitor of Chk2 and CDK2 with IC50 of 1.5 μM and 0.16 μM, respectively. SCH 900776 shows no significant inhibition of cytochrome P450 human liver microsomal isoforms 1A2, 2C9, 2C19, 2D6, and 3A4. SCH 900776 induces a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhances the γ-H2AX response of hydroxyurea, 5-fluoruracil, and cytarabine. In combination with an antimetabolite, SCH 900776 induces accumulation of γ-H2AX within 2 hours, indicative of replication fork collapse and double stranded DNA breaks. Additionally, SCH 900776 suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Exposure of proliferating WS1 cells to SCH 900776 is associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to SCH 900776 as part of a futile cycle, perhaps driven by AT-family kinases and DNA-PK.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPsNlAxNzJyMECgcm0> M2[4R|I1KGh? NUC0VnZX\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
HCT115 NX3uTYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTwNlAxNzJyMECgcm0> NITOeYszPCCq NUnCSlhZ\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MmfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
SW620 NVLy[FNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rMZVIxOC9{MECwJI5O MWeyOEBp NUjpTVNY\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NGLjTWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
IGROV-1 M37Gdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfoNlAxNzJyMECgcm0> NHTFRlMzPCCq NVjFc5dO\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NYnx[GpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
HCT116 NXLDWVhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrDNlAxNzJyMECgcm0> MmfQNlQhcA>? Mnuy[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n M{TDNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
MCF10A NYHHbXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;jTlIxOC9{MECwJI5O MlrXNlQhcA>? NIPVXmxl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NYPGR49iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
MiaPaCa-2 M{Xte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuyNFAwOjByMDDuUS=> NVvrN49FOjRiaB?= M2PPNoRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
MDA-MB-231 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKyNFAwOjByMDDuUS=> NVzVS2NLOjRiaB?= MWLk[YNz\WG|ZYOgeIhmKEmFNUCgc4YhT2WvY3n0ZYJqdmV? M4XwSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
HCC2998 M2rhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr4SGIzODBxMkCwNEBvVQ>? MlizNlQhcA>? MlzR[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n M{nXW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{W5OVI3Lz5{NEO1PVUzPjxxYU6=
U87 NGTwXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G1SFIxOC9{MECwJI5O NHHpSJozPCCq NIXtPIRl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
MDA-MB-435 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDoZngzODBxMkCwNEBvVQ>? MlXyNlQhcA>? M1HBV4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NILhRlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
SNB19 NYnuSnFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrrWHNpOjByL{KwNFAhdk1? MVeyOEBp Mork[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NUXMWXFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOVk2OjZpPkK0N|U6PTJ4PD;hQi=>
U20S M{W2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX2NlAxNzJyMECgcm0> NUTaR2p[OjRiaB?= NHrNbXhl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN3OUWyOkc,OjR|NUm1NlY9N2F-
A498 NX\mUHp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPTW5NrOjByL{KwNFAhdk1? NFXnNIozPCCq MmCw[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NFzOVFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1PVUzPid-MkSzOVk2OjZ:L3G+
TK10 MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKyNFAwOjByMDDuUS=> M3m4SVI1KGh? MmjI[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n MkHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
AsPC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2yNFAwOjByMDDuUS=> NWLNZoJUOjRiaB?= M3XoUYRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= Mo[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|NUm1NlYoRjJ2M{W5OVI3RC:jPh?=
H23 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\4RY1jPTByIH7N MnTkNlQhcA>? NGq4UZFFVVOR MWflcohidmOnczD0bIUh[2inbX;z[Y5{cXSrenH0bY9vKHSxIGDNXC=> MmjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUO1OFkoRjJ2MUGzOVQ6RC:jPh?=
H1437 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fPelUxOCCwTR?= NEHJO5AzPCCq M2LvSWROW09? MnL1[Y5p[W6lZYOgeIhmKGOqZX3vd4Vve2m2aYrheIlwdiC2bzDQUXg> M2XyOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUGzOVQ6Lz5{NEGxN|U1QTxxYU6=
H1993 M4nvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLvcIo2ODBibl2= NUnnWno5OjRiaB?= NWnaSGRCTE2VTx?= MXLlcohidmOnczD0bIUh[2inbX;z[Y5{cXSrenH0bY9vKHSxIGDNXC=> MlnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUO1OFkoRjJ2MUGzOVQ6RC:jPh?=
H1299 NWHkTI57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\POVAxKG6P NHTmZYEzPCCq MYTEUXNQ M37KR4VvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z NWKyfnhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNVM2PDlpPkK0NVE{PTR7PD;hQi=>
AsPC-1 NEjUNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nENlExNTFyMECgcm0> M3n5fFI1NTR6aB?= M4S0WYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> NFvkfpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
MiaPaCa-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW4UXEyOC1zMECwJI5O MnexNlQuPDiq M2HSWYVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> NFf5c4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwOFQzOid-MkO4NFQ1OjJ:L3G+
BxPC-3 M3;EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljkNVAuOTByMDDuUS=> NH\F[XUzPC12OHi= M{foVIVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:g[4Vu[2m2YXLpcoU> NX31c5RPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NFQ1OjJpPkKzPFA1PDJ{PD;hQi=>
SKOV3 NGPHeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOwMlMhyrWP M4TQdlgh\A>? NY\5fpAze2Wwc3n0bZpmeyC2aHWgZ4VtdCCuaX7ld{B1dyCpZX3jbZRi[mmwZdMg M2K0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUS4NlY6Lz5{M{W0PFI3QTxxYU6=
OVCAR-8 NVjyVGVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjYN415OC5|INM1US=> NUTXeJY{QCCm NXHITWlVe2Wwc3n0bZpmeyC2aHWgZ4VtdCCuaX7ld{B1dyCpZX3jbZRi[mmwZdMg NEP4NnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0PFI3QSd-MkO1OFgzPjl:L3G+
MV-4-11 Moi4RZBweHSxc3nzJGF{e2G7 MYWxNFAuPzByIH7N NF3ybIk1QCCq NXfybVlTcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> NYnoTYRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N|Y4OjFpPkKzOVM3PzJzPD;hQi=>
U937 NEHsZZNCeG:ydH;zbZMhSXO|YYm= NHjCeIYyODBvN{CwJI5O MUm0PEBp NXfBbnNXcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MofMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{[3NlEoRjJ|NUO2O|IyRC:jPh?=
MOLM-13  MUDBdI9xfG:|aYOgRZN{[Xl? M1mzXFExOC15MECgcm0> NF\W[mM1QCCq MmHrbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NU\wemFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1N|Y4OjFpPkKzOVM3PzJzPD;hQi=>
A2058  MoXpR4VtdCCYaXHibYxqfHliQYPzZZk> M3LnPFM4NjVvM{CwJI5O MmDOO|IhcA>? NXfQe2hQTE2VTx?= M3HBV5Jm\HWlZYOgeIhmKE2NLUG3O|UhTUN3MNMgZpkhPS2ob3zkJJRwKGGwIHH2[ZJi\2Vib3[gOFUhdk1? NIrwPIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0PFY5PCd-MkOxOFg3QDR:L3G+
H2009 NFjmPHdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVm1NFAhdk1? NE\BSZk4OiCq NYnNRZlSTE2VTx?= M3T1PJJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 NUfke3dDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOFg3QDRpPkKzNVQ5Pjh2PD;hQi=>
Su.86.86 NWXHd411S2WubDDWbYFjcWyrdImgRZN{[Xl? NVr5RnB5PTByIH7N Ml;oO|IhcA>? NW\KUXI4TE2VTx?= M2\qNJJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 NF3TcYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0PFY5PCd-MkOxOFg3QDR:L3G+
HRE NWOxN4tqS2WubDDWbYFjcWyrdImgRZN{[Xl? MUO1NFAhdk1? M1jze|czKGh? MVfEUXNQ MoK2doV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O|U> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF2OE[4OEc,OjNzNEi2PFQ9N2F-
HMEC Mo\sR4VtdCCYaXHibYxqfHliQYPzZZk> M2r5cFUxOCCwTR?= M{\4dVczKGh? NX\nc5FpTE2VTx?= NVraSFJLemW|dXz0d{BqdiCJMT;TMZBp[XOnIHHjZ5VufWyjdHnvckBkd22kaX7l[EB4cXSqIF3LMVE4PzV? NGjX[GE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G0PFY5PCd-MkOxOFg3QDR:L3G+
U2OS  MUfGeY5kfGmxbjDBd5NigQ>? Ml;hNkDDvU1? NU\VbW9tOC1{NDDo NYfkbWJPcW6mdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMTDheEB{\XKrbnWgN|Q2KGG2IHLveIgh[2:wY3XueJJifGmxboOgZZMh\WG{bImgZZMhOiCqIHHmeIVzKGGmbXnubZN1emG2aX;u NXLa[2EyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N|cyPDdpPkKyPVM4OTR5PD;hQi=>
U2OS  NIniVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\pNE0yOCEEtV2= NGXOcpIzPC92ODDo MkHQbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M1rQVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUO3NVQ4Lz5{MkmzO|E1PzxxYU6=
U937 NH3VfVlHfW6ldHnvckBCe3OjeR?= NWK2eZo6OTByLUWwNEBvVQ>? NULQTGRHPCCqwrC= NYjVeYhy\GWlcnXhd4V{KHSqZTDjfZRiemGkaX7lMYlv\HWlZXSgR4hsOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejJ7NtMgZY5lKHC{ZY\lcpR{KEOmY{K1RUBld3ewcnXneYxifGmxbh?= NYXROo5NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
U937 NFL2WYRHfW6ldHnvckBCe3OjeR?= MmS3NVAxKG6P M4rPT|QhcMLi MoqwdoV3\XK|ZYOgeIhmKGO7dHHyZYJqdmVvaX7keYNm\CCrbnjpZol1cW:wIH;mxsA{UC22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBqdnSxIFTORS=> Mn\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Nkm4OlkoRjJ{OE[5PFY6RC:jPh?=
U937 NYmzPXNrTnWwY4Tpc44hSXO|YYm= NIfxTnoyODBvNUCwJI5O MnrqOEBpyqB? MWDpcoR2[2W|IHnuZ5Jm[XOnZDDwbI9{eGixconsZZRqd25ib3[gTFJCYA>? M2\OV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OE[5PFY6Lz5{Mki2PVg3QTxxYU6=
HL-60 MkHCRZBweHSxc3nzJGF{e2G7 MlzNN|AwOTByL{OwNEBvVQ>? NVjjc|A6OjRiaB?= M4HoSmROW09? M{fJTIVvcGGwY3XzJIN6fGG{YXLpcoUucW6mdXPl[EBieG:ydH;zbZM> NHSxZmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2PVg3QSd-MkK4Olk5Pjl:L3G+
ML-1 MkLuRZBweHSxc3nzJGF{e2G7 MUmyOU82OC9zMECgcm0> NFq5clYzPCCq Mnr3SG1UVw>? M3zFeIVvcGGwY3XzJIN6fGG{YXLpcoUucW6mdXPl[EBieG:ydH;zbZM> NWjobmNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4Olk5PjlpPkKyPFY6QDZ7PD;hQi=>
HCT116 MUXGeY5kfGmxbjDBd5NigQ>? NHzsfGgyKML3TR?= MVeyOEBp NHPBeIdi[nKxZ3H0[ZMhd2ZiY3XscEBkgWOuZTDhdpJme3UEoB?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjVzMEW2NEc,OjJ3MUC1OlA9N2F-
U2OS MV3GeY5kfGmxbjDBd5NigQ>? M2HPVlEhyrWP MlvPNlQhcA>? NHXD[5li[nKxZ3H0[ZMhd2ZiY3XscEBkgWOuZTDhdpJme3UEoB?= NF;EVXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxNFU3OCd-MkK1NVA2PjB:L3G+
Sf9 MWLGeY5kfGmxbjDhd5NigQ>? M1LPRWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMOi:FeXPsbY4hSSCneIDy[ZN{\WRiaX6gbY5{\WO2IGPmPUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGuzN3BeNUGWUDDpcoNwenCxcnH0bY9vKGmwdH:gZolwfGmweXzheIVlKGirc4TvcoUhUDFiYX\0[ZIhOSCqcjDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMU[g{txONg>? NHL0dFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC5OFYxPyd-MkGwPVQ3ODd:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-chk1(ser345) / CDC25A ; 

PubMed: 27690219     


Western blots for H1299 and A549 cells treated with MK-8776 for various times and assessed for expression of p-chk1 (ser345) and CDC25A.

Cyclin E / pY15-CDK / γH2AX ; 

PubMed: 26595527     


The indicated cell lines were incubated with 2 μM of each drug for 6 h, then lysed and analyzed by western blotting. The top row reflects cells sensitive to MK-8776. The second row reflects cells that are also sensitive to MK-8776, but which fail to degrade cyclin E. The third row reflects MK-8776-resistant cell lines.

27690219 26595527
In vivo Administered 30 minutes after gemcitabine, 4 mg/kg SCH 900776 is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or SCH 900776 alone. Dose escalation of SCH 900776 (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response. Importantly, doses of SCH 900776 associate with robust biomarker activation and improved tumor response are not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. [1]

Protocol

Animal Research:[1]
- Collapse
  • Animal Models: Female nude mice injected subcutaneously with A2780 or MiaPaCa2 cells
  • Dosages: ~50 mg/kg
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 3 mg/mL (7.97 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% propylene glycol
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.25
Formula

C15H18BrN7

CAS No. 891494-63-6
Storage powder
in solvent
Synonyms N/A
Smiles CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

  • Answer:

    Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products

Tags: buy MK-8776|MK-8776 ic50|MK-8776 price|MK-8776 cost|MK-8776 solubility dmso|MK-8776 purchase|MK-8776 manufacturer|MK-8776 research buy|MK-8776 order|MK-8776 mouse|MK-8776 chemical structure|MK-8776 mw|MK-8776 molecular weight|MK-8776 datasheet|MK-8776 supplier|MK-8776 in vitro|MK-8776 cell line|MK-8776 concentration|MK-8776 nmr|MK-8776 in vivo|MK-8776 clinical trial|MK-8776 inhibitor|MK-8776 Cell Cycle inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID